American Century Companies Inc. Sells 156,853 Shares of Intuitive Surgical, Inc. $ISRG

American Century Companies Inc. decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,006,387 shares of the medical equipment provider’s stock after selling 156,853 shares during the quarter. Intuitive Surgical comprises approximately 0.5% of American Century Companies Inc.’s portfolio, making the stock its 17th biggest position. American Century Companies Inc. owned 0.56% of Intuitive Surgical worth $897,319,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Intuitive Surgical in the 2nd quarter worth about $2,569,260,000. Rakuten Investment Management Inc. purchased a new position in shares of Intuitive Surgical during the third quarter valued at about $388,436,000. Vanguard Group Inc. raised its stake in Intuitive Surgical by 2.1% in the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after buying an additional 670,302 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Intuitive Surgical by 27.1% in the second quarter. Canada Pension Plan Investment Board now owns 1,089,293 shares of the medical equipment provider’s stock worth $591,933,000 after buying an additional 231,980 shares in the last quarter. Finally, Winslow Capital Management LLC lifted its holdings in Intuitive Surgical by 20.2% in the second quarter. Winslow Capital Management LLC now owns 1,342,473 shares of the medical equipment provider’s stock worth $729,513,000 after buying an additional 225,545 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Intuitive Surgical news, EVP Myriam Curet sold 421 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total transaction of $208,378.16. Following the sale, the executive vice president directly owned 409 shares in the company, valued at approximately $202,438.64. This trade represents a 50.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 464 shares of Intuitive Surgical stock in a transaction on Monday, December 15th. The stock was sold at an average price of $548.49, for a total value of $254,499.36. Following the completion of the sale, the senior vice president directly owned 131 shares of the company’s stock, valued at approximately $71,852.19. The trade was a 77.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 56,409 shares of company stock valued at $30,895,377. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Price Performance

ISRG opened at $503.51 on Friday. The firm has a market cap of $178.81 billion, a PE ratio of 63.82, a P/E/G ratio of 3.91 and a beta of 1.65. The stock has a 50-day moving average price of $529.83 and a 200-day moving average price of $511.48. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. The business had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. Intuitive Surgical’s revenue was up 18.8% compared to the same quarter last year. During the same period last year, the business earned $2.21 EPS. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on ISRG shares. Citigroup reiterated a “neutral” rating and set a $590.00 target price (down from $635.00) on shares of Intuitive Surgical in a report on Friday, January 23rd. Royal Bank Of Canada lifted their price target on Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Evercore reduced their price target on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating on the stock in a research note on Friday, January 23rd. Truist Financial raised their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Robert W. Baird dropped their target price on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $615.86.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.